Phosphodiesterase type 5 inhibition improves arterial stiffness after exercise but not exercise capacity in hypertensive men

American Journal of Hypertension

Volumn 26, Issue 3, 2013, Pages 342-350

  Attinà, Teresa M ^a   Drummond, Iain D ^a   Malatino, Lorenzo S ^b   Maxwell, Simon R ^a   Webb, David J ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF CATANIA   (Italy)

Author keywords

blood pressure; exercise capacity; hypertension; nitric oxide; phosphodiesterase type 5 (PDE5); pulse wave velocity; sildenafil (Viagra )

Indexed keywords

HYDRALAZINE; PLACEBO; SILDENAFIL;

ADULT; AGED; ARTERIAL STIFFNESS; ARTICLE; BLOOD PRESSURE MEASUREMENT; CONTROLLED STUDY; CROSSOVER PROCEDURE; EXERCISE; HUMAN; HYPERTENSION; HYPOTHESIS; MALE; OXYGEN CONSUMPTION; PEAK OXYGEN UPTAKE; PRIORITY JOURNAL; PULSE WAVE; RANDOMIZED CONTROLLED TRIAL;

ADULT; BLOOD PRESSURE; EXERCISE; EXERCISE TOLERANCE; HUMANS; HYDRALAZINE; HYPERTENSION; MALE; MIDDLE AGED; OXYGEN CONSUMPTION; PHOSPHODIESTERASE 5 INHIBITORS; PIPERAZINES; PULSE WAVE ANALYSIS; PURINES; SULFONES; VASCULAR STIFFNESS;

EID: 84876565000     PISSN: 08957061     EISSN: 19417225     Source Type: Journal    
DOI: 10.1093/ajh/hps057     Document Type: Article

References (40)

1. Lim PO, MacFadyen RJ, Clarkson PB, MacDonald TM. Impaired exercise tolerance in hypertensive patients. Ann Intern Med 1996; 124:41-55. (Pubitemid 26019624)
2. Myers J, Prakash M, Froelicher V, Do D, Partington S, Atwood JE. Exercise capacity and mortality among men referred for exercise testing. N Engl J Med 2002; 346:793-801. (Pubitemid 34987553)
3. Munir S, Jiang B, Guilcher A, Brett S, Redwood S, Marber M, Chowienczyk P. Exercise reduces arterial pressure augmentation through vasodilation of muscular arteries in humans. Am J Physiol Heart Circ Physiol 2008; 294:H1645-1650. (Pubitemid 351490594)
4. Naka KK, Tweddel AC, Parthimos D, Henderson A, Goodfellow J, Frenneaux MP. Arterial distensibility: acute changes following dynamic exercise in normal subjects. Am J Physiol 2003; 284:H970-978. (Pubitemid 36228246)
5. Lund-Johansen P. Twenty-year follow-up of hemodynamics in essential hypertension during rest and exercise. Hypertension 1991; 18:III54-61.
6. Modesti PA, Olivo G, Pestelli F, Rocchi F, Vanni S, Tedeschini RC, Cecioni I, Gensini GF. Peripheral vascular resistance limits exercise functional capacity of mild hypertensives. Angiology 1999; 50:473-478. (Pubitemid 29277601)
7. Blair SN, Kohl HW 3rd, Barlow CE, Gibbons LW. Physical fitness and all-cause mortality in hypertensive men. Ann Med 1991; 23:307-312.
8. Church TS, Kampert JB, Gibbons LW, Barlow CE, Blair SN. Usefulness of cardiorespiratory fitness as a predictor of all-cause and cardiovascular disease mortality in men with systemic hypertension. Am J Cardiol 2001; 88:651-656. (Pubitemid 32834042)
9. Ceravolo R, Maio R, Pujia A, Sciacqua A, Ventura G, Costa MC, Sesti G, Perticone F. Pulse pressure and endothelial dysfunction in nevertreated hypertensive patients. J Am Coll Cardiol 2003; 41:1753-1758. (Pubitemid 36584248)
10. Laurent S, Boutouyrie P. Recent advances in arterial stiffness and wave reflection in human hypertension. Hypertension 2007; 49:1202-1206. (Pubitemid 46809353)
11. Stewart KJ, Sung J, Silber HA, Fleg JL, Kelemen MD, Turner KL, Bacher AC, Dobrosielski DA, DeRegis JR, Shapiro EP, Ouyang P. Exaggerated exercise blood pressure is related to impaired endothelial vasodilator function. Am J Hypertens 2004; 17:314-320. (Pubitemid 38446845)
12. Tsioufis C, Dimitriadis K, Thomopoulos C, Tsiachris D, Selima M, Stefanadi E, Tousoulis, Kallikazaros I, Stefanadis C. Exercise blood pressure response, albuminuria and arterial stiffness in hypertension. Am J Med 2008; 121:894-902.
13. Wilkinson IB,Qasem A, McEniery CM, Webb DJ, Avolio AP, Cockcroft JR. Nitric oxide regulates local arterial distensibility in vivo. Circulation 2002; 105:213-217. (Pubitemid 34084321)
14. Rybalkin SD, Yan C, Bornfeldt KE, Beavo JA. Cyclic GMP phosphodiesterases and regulation of smooth muscle function. Circ Res 2003; 93:280-291. (Pubitemid 37048240)
15. Omori K, Kotera J. Overview of PDEs and their regulation. Circ Res 2007; 100:309-327.
16. Galie N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, Fleming T, Parpia T, Burgess G, Branzi A, Grimminger F, Kurzyna M, Simonneau G. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005; 353:2148-2157. (Pubitemid 41653106)
17. Lewis GD, Lachmann J, Camuso J, Lepore JJ, Shin J, Martinovic ME, Systrom DM, Bloch KD, Semigran MJ. Sildenafil improves exercise hemodynamics and oxygen uptake in patients with systolic heart failure. Circulation 2007; 115:59-66. (Pubitemid 46058612)
18. Guazzi M, Vicenzi M, Arena R, Guazzi MD. PDE5 inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure. Circ Heart Fail 2011; 4:8-17.
19. Oliver JJ, Melville VP, Webb DJ. Effects of regular phosphodiesterase type 5 inhibition in hypertension. Hypertension 2006; 48:622-627. (Pubitemid 44843865)
20. Oliver JJ, Dear JW, Webb DJ. Clinical potential of combined organic nitrate and phosphodiesterase type 5 inhibitor in treatment-resistant hypertension. Hypertension 2010; 56:62-67.
21. Wolk R, Smith WB, Neutel JM, Rubino J, Xuan D, Mancuso J, Gilbert J, Pressler ML. Blood pressure lowering effects of a new long-acting inhibitor of phosphodiesterase 5 in patients with mild to moderate hypertension. Hypertension 2009; 53:1091-1097.
22. Attina TM, Malatino LS, Maxwell SR, Padfield PL, Webb DJ. Phosphodiesterase type 5 inhibition reverses impaired forearm exercise-induced vasodilatation in hypertensive patients. J Hypertens 2008; 26:501-507. (Pubitemid 351317259)
23. Wasserman K, Hansen JE, Sue DY, Casaburi R, Whipp BJ. Principles of Exercise Testing and Interpretation. 3rd ed. Baltimore: Lippincott Williams & Wilkins; 1999.
24. O'Brien E, Mee F, Atkins N, Thomas M. Evaluation of three devices for self-measurement of blood pressure according to the revised British Hypertension Society Protocol: the Omron HEM-705CP, Philips HP5332, and Nissei DS-175. Blood Press Monit 1996; 1:55-61. (Pubitemid 126441351)
25. Beaver WL, Wasserman K, Whipp BJ. A new method for detecting anaerobic threshold by gas exchange. J Appl Physiol 1986; 60: 2020-2027. (Pubitemid 16066969)
26. Cameron JD, Stevenson I, Reed E, McGrath BP, Dart AM, Kingwell BA. Accuracy of automated auscultatory blood pressure measurement during supine exercise and treadmill stress electrocardiogram-testing. Blood Press Monit 2004; 9:269-275. (Pubitemid 40125500)
27. Lim PO, Shiels P, MacDonald TM. The Dundee Step Test: a novel exercise test suitable for the outpatient management of hypertension. J Hypertens 1998; 16:1701. (Pubitemid 28515498)
28. Mulvihill-Wilson J, Gaffney FA, Neal WW, Graham RM, Pettinger WA, Blomqvist CG. Single and combined therapy for systemic hypertension with propranolol, hydralazine and hydrochlorothiazide: hemodynamic and neuroendocrine mechanisms of action. Am J Cardiol 1985; 56:315-320. (Pubitemid 15045239)
29. Tomlinson B, Bompart F, Graham BR, Liu JB, Prichard BN. Vasodilating mechanism and response to physiological pressor stimuli of acute doses of carvedilol compared with labetalol, propranolol and hydralazine. Drugs 1988; 36(Suppl 6):37-47. (Pubitemid 19205994)
30. Shepherd AM, Ludden TM, McNay JL, Lin MS. Hydralazine kinetics after single and repeated oral doses. Clin Pharmacol Ther 1980; 28:804-811. (Pubitemid 11213117)
31. Muirhead GJ, Rance DJ, Walker DK, Wastall P. Comparative human pharmacokinetics and metabolism of single-dose oral and intravenous sildenafil. Br J Clin Pharmacol 2002; 53(Suppl 1):13S-20S.
32. Fagan TC, Sternleib C, Vlachakis N, Deedwania PC, Mehta JL. Efficacy and safety comparison of nitrendipine and hydralazine as antihypertensive monotherapy. J Cardiovasc Pharmacol 1984; 6(Suppl 7):S1109-1113. (Pubitemid 15085440)
33. Goodman JM, McLaughlin PR,Plyley MJ, Holloway RM, Fell D, Logan AG, Liu PP. Impaired cardiopulmonary response to exercise in moderate hypertension. Can J Cardiol 1992; 8:363-371.
34. Guazzi M, Tumminello G, Di Marco F, Fiorentini C, Guazzi MD. The effects of phosphodiesterase-5 inhibition with sildenafil on pulmonary hemodynamics and diffusion capacity, exercise ventilatory efficiency, and oxygen uptake kinetics in chronic heart failure. J Am Coll Cardiol 2004; 44:2339-2348. (Pubitemid 39647608)
35. Palatini P. Exercise haemodynamics in the normotensive and the hypertensive subject. Clin Sci (Lond) 1994; 87:275-287. (Pubitemid 24285269)
36. Lewis GD, Shah R, Shahzad K, Camuso JM, Pappagianopoulos PP, Hung J, Tawakol A, Gerszten RE, Systrom DM, Bloch KD, Semigran MJ. Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension. Circulation 2007; 116:1555-1562. (Pubitemid 47511419)
37. Hsu AR, Barnholt KE, Grundmann NK, Lin JH, McCallum SW, Friedlander AL. Sildenafil improves cardiac output and exercise performance during acute hypoxia, but not normoxia. J Appl Physio. 2006; 100:2031-2040. (Pubitemid 43845879)
38. Aversa A, Vitale C, Volterrani M, Fabbri A, Spera G, Fini M, Rosano GM. Chronic administration of sildenafil improves markers of endothelial function in men with type 2 diabetes. Diabet Med 2008; 25:37-44.
39. Bocchi EA, Guimaraes G, Mocelin A, Bacal F, Bellotti G, Ramires JF. Sildenafil effects on exercise, neurohormonal activation, and erectile dysfunction in congestive heart failure: a double-blind, placebocontrolled, randomized study followed by a prospective treatment for erectile dysfunction. Circulation 2002; 106:1097-1103. (Pubitemid 34970850)
40. Michelakis E, Tymchak W, Lien D, Webster L, Hashimoto K, Archer S. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. Circulation 2002; 105:2398-2403. (Pubitemid 34556392)